Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes

Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nina A. Petunina, Milena Е. Telnova
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2018
Materias:
Acceso en línea:https://doaj.org/article/e01b1b31cbfe4e638bb0fff9a524daf6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e01b1b31cbfe4e638bb0fff9a524daf6
record_format dspace
spelling oai:doaj.org-article:e01b1b31cbfe4e638bb0fff9a524daf62021-11-14T09:00:21ZDiabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes2072-03512072-037810.14341/DM9623https://doaj.org/article/e01b1b31cbfe4e638bb0fff9a524daf62018-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9623https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available data, a significant decrease in the incretin effect is observed in patients with type 2 diabetes and obese individuals. Thus, a decrease in the incretin effect leads to a violation of the insulin response to the intake of carbohydrates, and, consequently, an increase in the level of glucose in the blood. It was also found that the decrease in the incretin effect in patients with type 2 diabetes can be associated with a lower secretion of glucagon-like peptide-1. The interest is represented by groups of antidiabetic drugs capable of regulating glycemia by affecting the secretion of insulin and glucagon, depending on its level. Such drugs include glucagon-like peptide-1 receptor agonists. The article shows the advantage of prolonged action in patients with type 2 diabetes and obesity of the glucagon-like peptide 1 receptor agonists (albiglutide, dulaglutide, exenatide with slow release) dosing 1 time a week.Nina A. PetuninaMilena Е. TelnovaEndocrinology Research Centrearticletype 2 diabetesobesityincretinsglucagon-like peptide-1Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 4, Pp 293-300 (2018)
institution DOAJ
collection DOAJ
language EN
RU
topic type 2 diabetes
obesity
incretins
glucagon-like peptide-1
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle type 2 diabetes
obesity
incretins
glucagon-like peptide-1
Nutritional diseases. Deficiency diseases
RC620-627
Nina A. Petunina
Milena Е. Telnova
Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
description Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available data, a significant decrease in the incretin effect is observed in patients with type 2 diabetes and obese individuals. Thus, a decrease in the incretin effect leads to a violation of the insulin response to the intake of carbohydrates, and, consequently, an increase in the level of glucose in the blood. It was also found that the decrease in the incretin effect in patients with type 2 diabetes can be associated with a lower secretion of glucagon-like peptide-1. The interest is represented by groups of antidiabetic drugs capable of regulating glycemia by affecting the secretion of insulin and glucagon, depending on its level. Such drugs include glucagon-like peptide-1 receptor agonists. The article shows the advantage of prolonged action in patients with type 2 diabetes and obesity of the glucagon-like peptide 1 receptor agonists (albiglutide, dulaglutide, exenatide with slow release) dosing 1 time a week.
format article
author Nina A. Petunina
Milena Е. Telnova
author_facet Nina A. Petunina
Milena Е. Telnova
author_sort Nina A. Petunina
title Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
title_short Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
title_full Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
title_fullStr Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
title_full_unstemmed Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
title_sort diabetes and obesity. the role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
publisher Endocrinology Research Centre
publishDate 2018
url https://doaj.org/article/e01b1b31cbfe4e638bb0fff9a524daf6
work_keys_str_mv AT ninaapetunina diabetesandobesitytheroleofagonistsglucagonlikepeptide1ofinthetreatmentoftype2diabetes
AT milenaetelnova diabetesandobesitytheroleofagonistsglucagonlikepeptide1ofinthetreatmentoftype2diabetes
_version_ 1718429559978721280